OX401 / Valerio Therap - LARVOL DELTA

Onxeo Further strengthens its Board of Directors with two Seasoned Personalities from the Healthcare Sector (GlobeNewswire) - "Onxeo S.A...today announced the appointment of Dr Robert L. Coleman and Dr Jacques Mallet as independent members of the Board of Directors....Dr Robert L. Coleman, new independent member of the Board of Directors of Onxeo...'I am very honored to join the Board of Directors of Onxeo. As a cancer specialist, I have dedicated my entire career to improving the way we treat several types of cancer and I'm thrilled to bring my experience to support the development of Onxeo and its pipeline internationally, notably through clinical development in the United-States. Based on the extensive dataset collected so far by the team, I believe AsiDNA could change cancer treatment paradigm, especially in some selected combinations and represents a promising way to help patients in need.'"

Announcement • Media quote

[VIRTUAL] A new generation of PARP interfering drug candidates for cancer treatment (AACR 2021) - "This breakthrough decoy agonist action has already shown, using our lead compound AsiDNA™, target engagement, excellentsafety profile in humans, and importantly lack of acquired resistance. Our results provide a preclinical rationale for using OX413 as an immunomodulatory and “metabolic exhauster” agent, especially in appropriately molecularly selected patients with tumors showing metabolic deficiencies."

Breast Cancer • Oncology • Solid Tumor • CD8 • PARP1 • PTPRC

Onxeo Reports Full-Year 2020 Financial Results and Provides Business Update (GlobeNewswire) - "The preclinical proof of concept of one or more OX400 compounds, expected in 2021, will be the starting point for the activities necessary for entry into the clinic, potentially in combination with immunotherapy, within 12 to 18 months."

Preclinical • Oncology

Onxeo to Present New Preclinical Data at AACR 2021 (GlobeNewswire) - "Onxeo S.A...announced the presentation of preclinical data confirming the differentiated antitumoral properties of the drug candidates generated by platON™...in e-poster sessions during the American Association for Cancer Research (AACR 2021) virtual annual meeting on April 10, 2021. The first e-poster supports the ability of AsiDNA™...to prevent resistance to KRAS inhibitors (KRASi) emerging from drug-tolerant persister cells (DTC)...The second e-poster describes the mechanism of action of the molecules of the new OX400 family, specifically designed to interfere with PARP signaling and display immunomodulatory properties and metabolic effects."

Preclinical • Oncology

Onxeo Confirms in Preclinical Studies the Profile of OX401, a Potent PARP Agonist with Strong Anti-Tumor Activity and Immunological Properties (GlobeNewswire) - "Through its action on PARP and the activation of an antitumor immune response via the cGAS-STING pathway, OX401 has shown in vivo a higher potency of activity than current PARP inhibitors, as evidenced by complete control of tumor growth…In addition, this activity on PARP induces a strong engagement of the cGAS-STING pathway, as shown by the increase in key biomarkers of the tumor immune response….In these in vivo proof of efficacy studies, the therapeutic value of OX401 was further demonstrated, as it has now been shown that OX401 triggers robust local anti-tumor immunity involving both adaptive and innate immune responses, in mice bearing syngenic breast tumors."

Preclinical • Oncology

Onxeo reports full-year 2019 financial results and provides business update (GlobeNewswire) - "The study, sponsored by Gustave Roussy, will evaluate the effect of AsiDNA™ on the acquired resistance to PARP inhibitor niraparib in 2^nd line maintenance treatment of relapsed ovarian is currently under review by the French agency (ANSM) and Ethics Committee. Assuming the recruitment can start from mid-year, the Company aims to obtain preliminary results by year-end 2020 or early in 2021....Proof-of-concept preclinical studies of OX401 are ongoing with results expected this year."

Clinical data • New P1/2 trial • Preclinical • Gynecologic Cancers • Oncology • Ovarian Cancer • Solid Tumor

OX401, a new generation of PARP-interfering drug for cancer treatment (TAT 2020) - "This breakthrough MoA has already shown, using our lead compound AsiDNA, target engagement and excellent safety profile in humans and importantly lack of resistance in multiple preclinical studies. Our results provide a rationale for using OX401 as an immunomodulatory and “metabolic exhauster” agent, with a therapeutic interest in particular in appropriately selected tumors with metabolic deficiencies. Legal entity responsible for the study: Onxeo. Funding: Onxeo."

PARP

Onxeo to present next-generation PARP inhibitor, OX401, at the European ESMO-TAT Congress 2020 (Businesswire) - "Onxeo S.A...today announces that the Company will present first preclinical results on OX401, its next-generation PARP inhibitor (PARPi), during a poster session at the ESMO-TAT1 Congress 2020 dedicated to the research on targeted cancer therapies, to be held in Paris, France, on March 2-4, 2020...These data establish OX401 in the current cutting-edge areas of research and open up promising therapeutic prospects, by exploiting both its ability to exhaust the tumor cell without inducing resistance and its value in combination with immunotherapies.”"

Preclinical

Onxeo to present next-generation PARP inhibitor, OX401, at PARP & DDR inhibitors summit 2020 (GlobeNewswire) - "Onxeo S.A...today announces that the Company’s Chief Scientific Officer, Françoise Bono, will present OX401, a next-generation PARP inhibitor (PARPi) of the Company, during an oral presentation at the PARP & DDR Inhibitors Summit 2020 held in Boston, MA on January 29-30, 2020."

Clinical data